Arcutis Biotherapeutics shares are trading higher after Mizuho upgraded the stock from Neutral to Buy and raised its price target from $4 to $8.
Portfolio Pulse from Benzinga Newsdesk
Arcutis Biotherapeutics' stock (ARQT) has seen an increase in trading after Mizuho upgraded the stock from Neutral to Buy and increased the price target from $4 to $8.

January 03, 2024 | 6:04 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Mizuho upgraded Arcutis Biotherapeutics (ARQT) from Neutral to Buy and raised the price target from $4 to $8, indicating a positive outlook on the stock.
The upgrade by Mizuho from Neutral to Buy typically suggests a strong confidence in the company's future performance and is likely to instill positive sentiment among investors. The doubling of the price target from $4 to $8 is a significant change that could lead to increased investor interest and a potential rise in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100